HCAT Overview

Upcoming Investor Conferences: Health Catalyst, Inc. will participate in several investor conferences, including the Stephens Annual Investment Conference on November 19, 2025, and the Canaccord Genuity MedTech Forum on November 20, 2025, featuring key executives in discussions and meetings.

Company Overview: Health Catalyst is a leading provider of data and analytics technology for healthcare organizations, with over 1,100 clients relying on its solutions to drive clinical, financial, and operational improvements.

Technology and Services: The company offers a cloud-based technology ecosystem, Health Catalyst Ignite™, which utilizes AI-enabled data analytics to transform complex healthcare information into actionable insights.

Proven Impact: Health Catalyst has a multi-decade mission focused on delivering measurable results, claiming to have generated billions of dollars in improvements across healthcare systems worldwide.

Healthcare and Biotech Stock Gains: Several healthcare and biotech stocks saw significant increases in after-hours trading following earnings updates, with KalVista Pharmaceuticals rising 11.29% and Health Catalyst up 13.24%.

KalVista Pharmaceuticals Performance: The company reported a third-quarter net loss of $49.5 million, with net product revenue of $13.7 million, reflecting a larger loss compared to the previous year.

Health Catalyst Financials: Health Catalyst posted a third-quarter net loss of $22.2 million and a revenue decline to $76.3 million, while projecting Q4 2025 revenue of approximately $73.5 million.

Assertio Holdings and Other Stocks: Assertio Holdings reported a net income of $11.4 million, leading to an 8.30% stock increase, while Abeona Therapeutics is set to report its third-quarter results soon, with analysts expecting a loss.

Health Catalyst Financial Performance: For Q3 2025, Health Catalyst reported revenue of $76.32 million, unchanged from the previous year, with an EPS of $0.06, down from $0.07 a year ago.

Earnings Surprises: The company's revenue exceeded the Zacks Consensus Estimate by 1.66%, and it delivered a 20% EPS surprise compared to the consensus estimate of $0.05.

Investor Insights: Key metrics beyond headline numbers are crucial for understanding a company's performance and guiding investors' decisions regarding stock price projections.

Stock Recommendations: Zacks Investment Research highlighted five stocks with potential for significant growth, emphasizing opportunities in lesser-known stocks that have previously shown substantial returns.